why choose us

First received: May 22, 2023

Clinical Trial: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)

Brief Summary: This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Read more